SCHEMBL25226325

SCHEMBL25226325

CSc1ncc2cc(-c3ccc(Cl)cc3Cl)c(Cl)nc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.40
CRHR1 P34998 4/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
AURKA O14965 2/20 0.36
KDR P35968 2/20 0.36
AURKB Q96GD4 2/20 0.36
HPGD P15428 4/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 1/20 0.36
HSD11B1 P28845 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537180 1.00 HSP90AB1 (0.40) HSP90AB1CRHR1NPC1RAB9ACYP1A2
SCHEMBL25272190 0.87 MEN1 (0.34) HSP90AB1MEN1KMT2AAURKAKDR
SCHEMBL29537457 0.87 MEN1 (0.34) HSP90AB1MEN1KMT2AAURKAKDR
SCHEMBL29536567 0.85 AURKA (0.46) NPC1MEN1KMT2AAURKAKDR
SCHEMBL25272744 0.85 AURKA (0.46) NPC1MEN1KMT2AAURKAKDR
SCHEMBL19817044 0.80 FGFR1 (0.50) MEN1KMT2AAURKAKDRAURKB
SCHEMBL29536557 0.80 FGFR1 (0.50) MEN1KMT2AAURKAKDRAURKB
SCHEMBL25271883 0.79 PAK1 (0.43)
SCHEMBL30595855 0.79 PAK1 (0.43)
SCHEMBL25272665 0.79 AKT1 (0.40) TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 EP disclosed
WO-2022032071-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORPORATION (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 HSP90AB1 1039/4885CRHR1 2946/4885NPC1 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.